Statistical approaches to analyse interval-censored data in a confirmatory trial Margareta Puu, AstraZeneca Mölndal 26 April 2006.

Slides:



Advertisements
Similar presentations
COMPUTER INTENSIVE AND RE-RANDOMIZATION TESTS IN CLINICAL TRIALS Thomas Hammerstrom, Ph.D. USFDA, Division of Biometrics The opinions expressed are those.
Advertisements

Modeling of Data. Basic Bayes theorem Bayes theorem relates the conditional probabilities of two events A, and B: A might be a hypothesis and B might.
Survival Analysis. Key variable = time until some event time from treatment to death time for a fracture to heal time from surgery to relapse.
Survival Analysis-1 In Survival Analysis the outcome of interest is time to an event In Survival Analysis the outcome of interest is time to an event The.
Introduction to Survival Analysis October 19, 2004 Brian F. Gage, MD, MSc with thanks to Bing Ho, MD, MPH Division of General Medical Sciences.
Biostat/Stat 576 Chapter 6 Selected Topics on Recurrent Event Data Analysis.
Cox Model With Intermitten and Error-Prone Covariate Observation Yury Gubman PhD thesis in Statistics Supervisors: Prof. David Zucker, Prof. Orly Manor.
Statistical Issues in Contraceptive Trials
April 25 Exam April 27 (bring calculator with exp) Cox-Regression
Analysis of Time to Event Data
the Cox proportional hazards model (Cox Regression Model)
EPIDEMIOLOGY AND BIOSTATISTICS DEPT Esimating Population Value with Hypothesis Testing.
Nonparametric Estimation with Recurrent Event Data Edsel A. Pena Department of Statistics University of South Carolina Research.
Chapter 11 Survival Analysis Part 3. 2 Considering Interactions Adapted from "Anderson" leukemia data as presented in Survival Analysis: A Self-Learning.
Survival analysis1 Every achievement originates from the seed of determination.
PH6415 Review Questions. 2 Question 1 A journal article reports a 95%CI for the relative risk (RR) of an event (treatment versus control as (0.55, 0.97).
Point and Confidence Interval Estimation of a Population Proportion, p
Biostatistics in Research Practice Time to event data Martin Bland Professor of Health Statistics University of York
Chapter 11 Survival Analysis Part 2. 2 Survival Analysis and Regression Combine lots of information Combine lots of information Look at several variables.
Using Weibull Model to Predict the Future: ATAC Trial Anna Osmukhina, PhD Principal Statistician, AstraZeneca 15 April 2010.
Modeling clustered survival data The different approaches.
Sample Size Determination Ziad Taib March 7, 2014.
Survival Analysis A Brief Introduction Survival Function, Hazard Function In many medical studies, the primary endpoint is time until an event.
Analysis of Complex Survey Data
Survival Analysis: From Square One to Square Two
Survival analysis Brian Healy, PhD. Previous classes Regression Regression –Linear regression –Multiple regression –Logistic regression.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 10: Survival Curves Marshall University Genomics Core.
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
1 Survival Analysis Biomedical Applications Halifax SAS User Group April 29/2011.
Copyright © Leland Stanford Junior University. All rights reserved. Warning: This presentation is protected by copyright law and international.
NASSER DAVARZANI DEPARTMENT OF KNOWLEDGE ENGINEERING MAASTRICHT UNIVERSITY, 6200 MAASTRICHT, THE NETHERLANDS 22 OCTOBER 2012 Introduction to Survival Analysis.
HSRP 734: Advanced Statistical Methods July 10, 2008.
Dr Laura Bonnett Department of Biostatistics. UNDERSTANDING SURVIVAL ANALYSIS.
Biostatistics Case Studies 2005 Peter D. Christenson Biostatistician Session 4: Taking Risks and Playing the Odds: OR vs.
On Model Validation Techniques Alex Karagrigoriou University of Cyprus "Quality - Theory and Practice”, ORT Braude College of Engineering, Karmiel, May.
8.1 Inference for a Single Proportion
Random Sampling, Point Estimation and Maximum Likelihood.
1 Introduction to medical survival analysis John Pearson Biostatistics consultant University of Otago Canterbury 7 October 2008.
Bayesian Analysis and Applications of A Cure Rate Model.
Maximum Likelihood Estimator of Proportion Let {s 1,s 2,…,s n } be a set of independent outcomes from a Bernoulli experiment with unknown probability.
INTRODUCTION TO SURVIVAL ANALYSIS
Chapter 12 Survival Analysis.
01/20151 EPI 5344: Survival Analysis in Epidemiology Survival curve comparison (non-regression methods) March 3, 2015 Dr. N. Birkett, School of Epidemiology,
Introduction to Survival Analysis Utah State University January 28, 2008 Bill Welbourn.
Modeling Cure Rates Using the Survival Distribution of the General Population Wei Hou 1, Keith Muller 1, Michael Milano 2, Paul Okunieff 1, Myron Chang.
Generalized pairwise comparisons of prioritized outcomes Marc Buyse, ScD
HSRP 734: Advanced Statistical Methods July 31, 2008.
Empirical Efficiency Maximization: Locally Efficient Covariate Adjustment in Randomized Experiments Daniel B. Rubin Joint work with Mark J. van der Laan.
Pro gradu –thesis Tuija Hevonkorpi.  Basic of survival analysis  Weibull model  Frailty models  Accelerated failure time model  Case study.
Patricia Guyot1,2, Nicky J Welton1, AE Ades1
Introduction Sample Size Calculation for Comparing Strategies in Two-Stage Randomizations with Censored Data Zhiguo Li and Susan Murphy Institute for Social.
01/20151 EPI 5344: Survival Analysis in Epidemiology Actuarial and Kaplan-Meier methods February 24, 2015 Dr. N. Birkett, School of Epidemiology, Public.
Discrepancy between Data and Fit. Introduction What is Deviance? Deviance for Binary Responses and Proportions Deviance as measure of the goodness of.
Satistics 2621 Statistics 262: Intermediate Biostatistics Jonathan Taylor and Kristin Cobb April 20, 2004: Introduction to Survival Analysis.
We’ll now look at the relationship between a survival variable Y and an explanatory variable X; e.g., Y could be remission time in a leukemia study and.
1 Using dynamic path analysis to estimate direct and indirect effects of treatment and other fixed covariates in the presence of an internal time-dependent.
Treat everyone with sincerity,
Some survival basics Developments from the Kaplan-Meier method October
01/20151 EPI 5344: Survival Analysis in Epidemiology Hazard March 3, 2015 Dr. N. Birkett, School of Epidemiology, Public Health & Preventive Medicine,
INTRODUCTION TO CLINICAL RESEARCH Survival Analysis – Getting Started Karen Bandeen-Roche, Ph.D. July 20, 2010.
HYPOTHESIS TESTING FOR DIFFERENCES BETWEEN MEANS AND BETWEEN PROPORTIONS.
REGRESSION MODEL FITTING & IDENTIFICATION OF PROGNOSTIC FACTORS BISMA FAROOQI.
SURVIVAL ANALYSIS PRESENTED BY: DR SANJAYA KUMAR SAHOO PGT,AIIH&PH,KOLKATA.
Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.
Carolinas Medical Center, Charlotte, NC Website:
Comparing Cox Model with a Surviving Fraction with regular Cox model
Impact of censoring on the statistical methods for handling non-proportional hazards in Immuno-Oncology studies Yifan Huang, Luping Zhao, Jiabu Ye, and.
Meta-analysis of joint longitudinal and event-time outcomes
Jeffrey E. Korte, PhD BMTRY 747: Foundations of Epidemiology II
Presentation transcript:

Statistical approaches to analyse interval-censored data in a confirmatory trial Margareta Puu, AstraZeneca Mölndal 26 April 2006

Next 30 minutes Summary of some of the methods available to analyse interval- censored data Software that could be used for the analysis of interval-censored data A simplified approach that could be used in some situations

What is interval-censored data? The time of the event of interest is only known to have occurred within an interval of time Common in clinical trials, where patients are seen at pre- scheduled visits but the event of interest occurs in between visits

Example: A breast cancer study 94 patients randomised to two treatment groups: Radiation treatment and Combination treatment (Radiation treatment + Chemotherapy) The purpose was to compare the two treatments with the respect to the time to cosmetic deterioration Patients were supposed to be seen at pre-scheduled visits every 4 to 6 months, but follow-up intervals were often longer. A typically observation for a patient that have had an event is recorded as an interval such as (6, 14] months. Therefore, the event of interest is only known to have occurred between two visits.

Consider the situation where data are interval-censored and individuals are randomised to two treatment groups. Suppose we would like to 1)Estimate and illustrate the survival distribution in each treatment group 2)Test the hypothesis whether there is a significant treatment effect or not by using a non-parametric test 3)Estimate the treatment effect and adjust the analysis for other covariates Suggested analyses

If the intervals between consecutive visits are short Then we could approximate the interval-censored observation by e.g. the midpoint of the interval-censored observation. Then we would get exact failure time data rather than interval- censored data, and well-known statistical methods developed for right-censored data could be used for the suggested analyses.

A simplified approach (midpoint imputation) 1.Use the Kaplan-Meier (KM) estimator to estimate and illustrate the survival distribution in each of the two treatment groups 2.Use the log-rank test to test the hypothesis whether there is a significant treatment effect or not 3.Fit a proportional hazards model to get an estimate of the treatment effect and adjust the analysis for other covariates

Important! Midpoint imputation is only reasonably when the time periods between consecutive visits are short. When the width of the interval increases, we may run into problems. Law and Brookmeyer (1992) showed that the statistical properties of midpoint imputation depend strongly on the width of the interval between visits. The authors noted that midpoint imputation, used to estimate the regression parameter in a proportional hazards model, might result in a biased estimate if the intervals are wide and varied. Also the standard error of the estimator is underestimated since midpoint imputation assumes that the failure times are exactly known when in fact they are not, (Kim 2003).

If the intervals are wide and varied 1.Use the non-parametric maximum likelihood estimator (NPMLE) to estimate and illustrate the survival distribution in each of the two treatment groups 2.Use a generalised log-rank test developed for interval-censored failure time data to test the hypothesis whether there is a significant treatment effect or not 3.Fit a regression model to the interval-censored observations to get an estimate of the treatment effect and to adjust the analysis for other covariates, e.g. fit an accelerated failure time (AFT) model to the interval- censored observations

1. The non-parametric maximum likelihood estimator Peto (1973) was the first to propose a non-parametric method for estimating the survival function based on interval-censored data Turnbull (1976) derived the same estimator, but used a different approach in estimation In R : The package Icens includes many functions for the calculation of the non-parametric maximum likelihood estimator In S-plus : Ongoing project to develop software that includes calculation of the non-parametric maximum likelihood estimator

2. The generalised log-rank test for interval-censored data Sun (2005) discussed the non-parametric comparison of survival functions when only interval-censored failure time data are available. He proposed a class of non-parametric tests and presented both finite and asymptotic properties of the proposed test statistics. The proposed test statistics are generalisations of the regular log-rank test. No software available

3. Regression models for interval-censored data Accelerated failure time (AFT) models can be fitted to interval-censored observations both in SAS and S-plus. Several different failure time distributions are available (e.g. Weibull and log-normal). AFT models involve stronger assumptions than e.g. the proportional hazards model. The proportional hazards model could be fitted to interval-censored data, but there is no commercial software available.

Example: A breast cancer study Radiation treatment Combination treatment

Example: A breast cancer study PatientLeftRightEventMidpoint Trt RRRCCCRRRCCC

Example: A breast cancer study Use the midpoints and the Kaplan-Meier estimator to estimate the survival functions for the two treatment groups Also use the non-parametric maximum likelihood estimator to estimate the survival functions for the two treatment groups Use the midpoints and perform a log-rank test Also perform the generalised log-rank test developed for interval-censored failure time data

Example: A breast cancer study Example: A breast cancer study The Kaplan-Meier estimator and the Non-Parametric Maximum Likelihood estimator

Example: A breast cancer study The log-rank test using the midpoints: p-value = The generalised log-rank test for interval-censored data: p-value = 0.007

References Alioum, A. and Commenges, D. (1996) A proportional Hazards Model for Arbitrarily Censored and Truncated Data. Biometrics 52, Finkelstein, D. (1986) A proportional Hazards Model for Interval-Censored Failure Time Data. Biometrics 42, Sun, J. (1996) A non-parametric test for interval-censored failure time data with application to aids studies. Statistics in Medicine 15, Sun, J. and Zhao, Q. (2005) Generalised Log-Rank Tests for Interval-Censored Failure Time Data. Scandinavian Journal of Statistics 32, Law, G. and Brookmeyer, R. (1992) Effects of mid-point imputation on the analysis of doubly censored data. Statistics in Medicine 11, Kim, J. (2003) Maximum likelihood estimation for the proportional hazards model with partly interval-censored data. J. R. Statist. Soc. B. 65,